Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium

  title={Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium},
  author={Frederic M{\'a}rmol},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • F. Mármol
  • Published 12 December 2008
  • Psychology, Biology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
Potential Mechanisms of Action of Lithium in Bipolar Disorder
It is clear that the processes which underpin the therapeutic actions of lithium are sophisticated and most likely inter-related.
Lithium in the Treatment of Bipolar Disorder: Evidence of Intracellular Mechanisms that Substantiate Two Prominent Theories of Action
Bipolar Disorder is a serious chronic illness that is disruptive to daily functioning and can be life threatening. Diagnosis is complex due to the variable nature of the disorder and symptoms.
Lithium: a review of pharmacology, clinical uses, and toxicity.
The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder.
A number of genes associated with bipolar disorder, including Comt (catechol-O-methyltransferase), Vapa (vesicle-associated membrane protein-associated protein A), Dtnb (dystrobrevin beta) and Pkd1 (polycystic kidney disease 1), were significantly altered in the microarray dataset along with genes associatedwith synaptic transmission, apoptosis and transport among other functions.
Lithium: Neurotransmission and Cellular Mechanism Pathways Underlying Neuroprogression in Bipolar Disorder
This chapter reviews the therapeutic effects of lithium on neurotransmission and cellular signal transduction mechanisms underlying neuroprogression in bipolar disorder and key glycogen synthase kinase-3β-mediated mechanisms are highlighted, as they appear pivotal to therapeutic response.
Bipolar Disorders and Lithium: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Lithium: Review of Articles
  • Medicine
  • 2016
Lithium is a mood stabilizer which is approved for use in acute and maintenance mania. It is the first medications approved for the treatment of bipolar disorders. The drug has narrow therapeutic
Lithium: a key to the genetics of bipolar disorder
Evidence suggests that individuals who respond well to lithium treatment have more homogeneous clinical and molecular profiles, and response to lithium seems to cluster in families and can be used as a predictor for recurrence of BD symptoms.
Lithium: the pharmacodynamic actions of the amazing ion
Support is provided for a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium, and how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases.
Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder
Preclinical findings have shown that the neuroprotective benefits of these agents facilitate anti-inflammation, angiogenesis, neurogenesis, blood-brain barrier integrity, and disease-specific neuroprotection, which can be compared with dysregulated disease mechanisms to suggest core cellular and molecular disturbances identifiable by specific risk biomarkers.


[Lithium: 55 years of history in the therapy of bipolar affective disorder].
It has yet to be determined which of these is the principal factor responsible for lithium's therapeutic action, while at the same time the possibility cannot be totally ruled out that its precise mechanism of action is still to be discovered.
Molecular effects of lithium.
Recent insights into lithium's actions are reviewed, leading to the strategic development of improved therapeutics for the treatment of bipolar disorder and its intracellular downstream targets including adenylate cyclase, the phosphoinositol cascade, arachidonic acid metabolism, and effects on neurotrophic cascade.
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
The task of developing novel medications for bipolar disorder is truly daunting, and it is hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
5-HT1B Receptors: A Novel Target for Lithium: Possible Involvement in Mood Disorders
The nature of bipolar disorder.
Regulation of gene expression and identification of factors regulating neuroplasticity and neurotrophic events in the central nervous system in bipolar disorder are 2 of the more recent approaches contributing to clarification of the pathophysiology and potential treatment options.
Endophenotypes in bipolar disorder.
Findings in patients with bipolar disorder that may eventually be useful as endophenotypes include abnormal regulation of circadian rhythms, response to sleep deprivation, P300 event-related potentials, behavioral responses to psychostimulants and other medications, Response to cholinergics, increase in white matter hyperintensities, and biochemical observations in peripheral mononuclear cells.
No association between the PREP gene and lithium responsive bipolar disorder
The findings do not support the hypothesis that genetic variation in this gene plays a major role in the etiology of BD or Li response, and PREP is an interesting candidate gene to investigate in genetic studies of BD.
Search for a common mechanism of mood stabilizers.
Bipolar disorder (BPD), the province of mood stabilizers, has long been considered a recurrent disorder. For more than 50 years, lithium, the prototypal mood stabilizer, has been known to be
A common mechanism of action for three mood-stabilizing drugs
It is shown that all three lithium, carbamazepine and valproic acid drugs inhibit the collapse of sensory neuron growth cones and increase growth cone area, suggesting a molecular basis for both bipolar affective disorder and its treatment.